NANOSPACER, a transparent coverslip paired with a bottom substrate, enables high-resolution particle observation at the nanoscale. Now Oliver Vanderpoorten, project lead for NANOSPACER, has found yet another use for this versatile device. Together with the German company Priavoid GmbH, he is exploring NANOSPACER for its application as drug discovery platform for Alzheimer’s disease and dementia.
NANOSPACER is published in the International Journal of Nanomedicine, for contributions to cancer research in collaboration with University of Bergen.
This month, NANOSPACER secured a 5 MNOK verification grant from the Research Council of Norway in collaboration with Norinnova and successfully underwent testing for nanobubble detection with SINTEF Ocean. With these milestones, the device is on a promising path towards real-world applications.
Centre for Digital Life Norway is a national centre for biotechnology research and innovation and is funded by the Research Council of Norway.
